Background: Recent studies have investigated the relationship between cadmium exposure and kidney stones. Nevertheless, the results remain controversial. Therefore, we performed a comprehensive systematic review and meta-analysis based on the latest evidence to address gaps in the research.Methods: Medline, Embase, and the Web of Science databases were searched to identify relevant studies up until 31 July 2024. Characteristics and outcomes of the included studies were extracted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines. A random effects model was used to determine the association between cadmium exposure and the risk of kidney stones.Results: A total of 17 studies involving 159,011 individuals were included in the meta-analysis. When comparing the highest versus lowest cadmium exposure levels, the overall relative risk (RR) for kidney stones was 1.19 [95% confidence interval (CI): 1.10–1.29]. Subgroup analysis showed that urinary (RR = 1.19; 95%CI: 1.08–1.30) and blood (RR = 1.49; 95% CI: 1.10–2.02) cadmium levels were associated with an increased risk of kidney stones. In contrast to non-cadmium-contaminated areas, both blood (RR = 1.08; 95% CI: 1.00–1.15) and urinary (RR = 1.16; 95% CI: 1.05–1.27) cadmium levels were associated with an increased risk of kidney stones in cadmium-contaminated areas. In the dose–response meta-analysis, we observed a consistent linear positive association between cadmium exposure and the risk of kidney stones. The overall RR for every 1.0 μg/L increase in urinary cadmium levels was 1.07 (95% CI: 1.01–1.13).Conclusion: Our findings suggest that cadmium exposure is associated with the risk of kidney stones. These findings reinforce the importance of environmental cadmium exposure as a risk factor for kidney stones, extending beyond the influence of conventional risk factors. Efforts to reduce cadmium exposure in the population may help reduce the individual, economic, and societal burdens associated with kidney stones.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/myprospero.
We present a 79-year-old male patient with MSI-H/TMB-H (91.5 mutations/Mb) metastatic castration-resistant prostate cancer who progressed following abiraterone and enzalutamide treatment. When toripalimab was started, his serum PSA was 102 ng/mL. We maintained androgen-deprivation therapy with leuprorelin and stopped enzalutamide. Toripalimab 240 mg was given intravenously every 21 days. His PSA dropped below 0.09 ng/mL after three treatment cycles. We retrospectively applied RECIST version 1.1 criteria and selected the locally invasive prostate-soft-tissue mass as our only measurable non-nodal target lesion. Its maximal diameter shrank from 119 mm at baseline to 43 mm after six cycles (63.9% reduction), and further to 31 mm after 25 cycles (73.9% reduction), satisfying criteria for partial response. Pelvic lymph nodes could only be classified as non-target disease because short-axis diameters were unavailable in imaging reports, though these nodes resolved on imaging after six cycles. Bone lesions were not included in RECIST response evaluation and were interpreted separately on serial bone scans. At cycle 31 (roughly 21 months after toripalimab commencement), PSA stayed undetectable without clinical or radiological signs of progression; the biochemical response persisted for about 19 months starting from cycle 3. As of manuscript revision, the patient remains on toripalimab plus leuprorelin with routine follow-up. No treatment-related adverse events were identified using CTCAE version 5.0. We also conducted a targeted narrative review of mCRPC cases treated with PD-1/PD-L1 inhibitors other than pembrolizumab. This single-case observation highlights the value of genomic profiling for mCRPC patients with relevant biomarkers. Readers should interpret these findings as hypothesis-generating and not proof of universal toripalimab activity.